Share Price and Basic Stock Data
Last Updated: December 25, 2025, 3:39 am
| PEG Ratio | -6.74 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Cohance Lifesciences Ltd operates in the pharmaceuticals sector and reported a price of ₹536 with a market capitalization of ₹20,492 Cr. The company has exhibited fluctuating revenue trends in recent quarters. Sales for the quarter ending June 2022 were ₹339 Cr, which peaked at ₹369 Cr in March 2023 but later declined to ₹231 Cr by September 2023. The company recorded a notable rebound with sales rising to ₹488 Cr in June 2024, followed by a further increase to ₹840 Cr in March 2025. Annual sales figures show a general upward trajectory, with revenues growing from ₹378 Cr in March 2019 to ₹1,340 Cr in March 2023, before declining slightly to ₹1,051 Cr in March 2024. The trailing twelve months (TTM) revenue stood at ₹2,252 Cr, indicating a robust recovery in the fiscal year. The volatility in sales reflects the competitive nature of the pharmaceutical industry, where demand can be influenced by various factors, including regulatory changes and market dynamics.
Profitability and Efficiency Metrics
The profitability metrics for Cohance Lifesciences Ltd reveal a mixed performance, with an operating profit margin (OPM) of 20% reflecting operational efficiency. OPM has shown volatility, peaking at 48% in June 2023 but declining to 20% by June 2025. The net profit for the company was reported at ₹313 Cr, with a corresponding return on equity (ROE) of 12.7% and return on capital employed (ROCE) at 14.9%. The interest coverage ratio (ICR) stood at a strong 35.12x, indicating that the company comfortably covers its interest obligations. However, net profit margins have fluctuated, decreasing from 30.68% in March 2023 to 22.10% in March 2025. The company’s ability to maintain profitability amidst rising expenses, which were ₹822 Cr in March 2025, is commendable but highlights the need for continued focus on cost management to sustain margins.
Balance Sheet Strength and Financial Ratios
Cohance Lifesciences Ltd maintains a relatively strong balance sheet, with total assets reported at ₹3,031 Cr and reserves of ₹3,749 Cr, indicating a solid equity base. The company has manageable borrowings amounting to ₹451 Cr, resulting in a total debt-to-equity ratio of 0.04, which is well within acceptable limits for the pharmaceutical industry. This low leverage suggests financial stability and reduced insolvency risk. The current ratio stands at 2.43, indicating that the company can cover its short-term liabilities comfortably. However, the price-to-book value (P/BV) ratio of 17.40x raises concerns about valuation, as it is significantly higher than typical sector averages. The high market capitalization relative to net operating revenue indicates investor optimism but also presents a risk if the company fails to deliver consistent growth. Overall, the financial ratios reflect a company that is leveraging its equity effectively while managing its liabilities prudently.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Cohance Lifesciences Ltd indicates a diversified ownership structure. Promoters hold 57.49% of the shares, while domestic institutional investors (DIIs) account for 20.81% and foreign institutional investors (FIIs) hold 6.51%. The public holds 15.16% of the equity, with a total of 75,284 shareholders. Over the past year, promoter shareholding has seen fluctuations, dropping to 50.10% in March 2025 before recovering to its current level. The DII shareholding has also experienced variations, peaking at 17.42% in June 2024 and currently standing at 20.81%. This suggests that institutional investors remain confident in the company’s prospects, despite some volatility. The gradual increase in DII participation could be interpreted as a positive signal, while the decrease in promoter stake might raise questions about long-term commitment. Overall, the diverse shareholder base indicates a balanced approach to corporate governance and investor relations.
Outlook, Risks, and Final Insight
The outlook for Cohance Lifesciences Ltd remains cautiously optimistic, driven by recent revenue recoveries and a solid balance sheet. However, the company faces risks that could impact its future performance. The pharmaceutical industry is highly competitive, and any regulatory changes could significantly affect operations. Additionally, the fluctuating profit margins highlight the need for effective cost control measures. The high P/BV ratio may also imply that the stock is overvalued, which could deter potential investors if performance does not meet expectations. As the company continues to navigate these challenges, maintaining operational efficiency and managing expenses will be crucial. Should Cohance Lifesciences Ltd successfully enhance its market position and stabilize its profit margins, it could position itself favorably for sustained growth. Conversely, failure to address these operational challenges may hinder its ability to capitalize on market opportunities, potentially affecting shareholder confidence and stock performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 231/84.3 | 29.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,770 Cr. | 438 | 479/192 | 98.8 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.7 Cr. | 33.3 | 35.0/17.0 | 116 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,181.97 Cr | 1,153.40 | 53.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 339 | 278 | 354 | 369 | 348 | 231 | 220 | 253 | 488 | 258 | 307 | 840 | 549 |
| Expenses | 188 | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 154 | 189 | 611 | 437 |
| Operating Profit | 151 | 100 | 147 | 172 | 167 | 98 | 66 | 73 | 125 | 104 | 118 | 229 | 112 |
| OPM % | 45% | 36% | 41% | 47% | 48% | 42% | 30% | 29% | 26% | 40% | 38% | 27% | 20% |
| Other Income | 11 | 11 | 13 | 11 | 11 | 20 | 14 | 17 | 19 | 14 | 16 | -4 | 6 |
| Interest | 1 | 0 | 1 | 5 | 1 | 0 | 2 | 2 | 10 | 2 | 3 | 10 | 10 |
| Depreciation | 12 | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 17 | 20 | 54 | 45 |
| Profit before tax | 149 | 98 | 146 | 166 | 164 | 105 | 65 | 71 | 103 | 100 | 110 | 161 | 63 |
| Tax % | 28% | 27% | 26% | 25% | 26% | 25% | 29% | 25% | 27% | 18% | 24% | 27% | 26% |
| Net Profit | 108 | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 82 | 83 | 117 | 46 |
| EPS in Rs | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 2.96 | 3.23 | 3.26 | 4.73 | 1.28 |
Last Updated: August 22, 2025, 10:42 am
Below is a detailed analysis of the quarterly data for Cohance Lifesciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 549.00 Cr.. The value appears to be declining and may need further review. It has decreased from 840.00 Cr. (Mar 2025) to 549.00 Cr., marking a decrease of 291.00 Cr..
- For Expenses, as of Jun 2025, the value is 437.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 611.00 Cr. (Mar 2025) to 437.00 Cr., marking a decrease of 174.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 112.00 Cr.. The value appears to be declining and may need further review. It has decreased from 229.00 Cr. (Mar 2025) to 112.00 Cr., marking a decrease of 117.00 Cr..
- For OPM %, as of Jun 2025, the value is 20.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Mar 2025) to 20.00%, marking a decrease of 7.00%.
- For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from -4.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 10.00 Cr..
- For Interest, as of Jun 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Depreciation, as of Jun 2025, the value is 45.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 54.00 Cr. (Mar 2025) to 45.00 Cr., marking a decrease of 9.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 63.00 Cr.. The value appears to be declining and may need further review. It has decreased from 161.00 Cr. (Mar 2025) to 63.00 Cr., marking a decrease of 98.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Mar 2025) to 26.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 46.00 Cr.. The value appears to be declining and may need further review. It has decreased from 117.00 Cr. (Mar 2025) to 46.00 Cr., marking a decrease of 71.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.28. The value appears to be declining and may need further review. It has decreased from 4.73 (Mar 2025) to 1.28, marking a decrease of 3.45.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:33 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 1,198 | 2,252 |
| Expenses | 206 | 449 | 567 | 738 | 766 | 645 | 822 | 1,673 |
| Operating Profit | 172 | 385 | 443 | 582 | 574 | 406 | 375 | 580 |
| OPM % | 45% | 46% | 44% | 44% | 43% | 39% | 31% | 26% |
| Other Income | 1 | 66 | 68 | 133 | 46 | 62 | 58 | 34 |
| Interest | 3 | 23 | 12 | 9 | 13 | 7 | 12 | 33 |
| Depreciation | 12 | 24 | 32 | 39 | 48 | 55 | 77 | 164 |
| Profit before tax | 158 | 405 | 468 | 668 | 560 | 406 | 344 | 417 |
| Tax % | 31% | 22% | 23% | 32% | 27% | 26% | 23% | |
| Net Profit | 109 | 317 | 362 | 454 | 411 | 300 | 265 | 313 |
| EPS in Rs | 12.45 | 14.23 | 17.83 | 16.16 | 11.80 | 10.52 | 11.21 | |
| Dividend Payout % | 0% | 20% | 14% | 28% | 37% | 0% | 0% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 190.83% | 14.20% | 25.41% | -9.47% | -27.01% | -11.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -176.63% | 11.22% | -34.89% | -17.54% | 15.34% |
Cohance Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | -3% |
| TTM: | 64% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -16% |
| TTM: | 38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 23% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 17% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: December 10, 2025, 3:29 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.00 | 13 | 25 | 25 | 25 | 25 | 25 | 38 |
| Reserves | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 | 3,749 |
| Borrowings | 83 | 186 | 143 | 97 | 70 | 65 | 279 | 451 |
| Other Liabilities | 123 | 142 | 151 | 205 | 160 | 138 | 1,056 | 1,330 |
| Total Liabilities | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 3,031 | 5,568 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 | 3,116 |
| CWIP | 111 | 102 | 96 | 30 | 165 | 179 | 256 | 357 |
| Investments | 7 | 338 | 542 | 598 | 536 | 904 | 337 | 454 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 725 | 1,641 |
| Total Assets | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 3,031 | 5,568 |
Below is a detailed analysis of the balance sheet data for Cohance Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 38.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 38.00 Cr., marking an increase of 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,749.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,671.00 Cr. (Mar 2025) to 3,749.00 Cr., marking an increase of 2,078.00 Cr..
- For Borrowings, as of Sep 2025, the value is 451.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 279.00 Cr. (Mar 2025) to 451.00 Cr., marking an increase of 172.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,330.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,056.00 Cr. (Mar 2025) to 1,330.00 Cr., marking an increase of 274.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,568.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,031.00 Cr. (Mar 2025) to 5,568.00 Cr., marking an increase of 2,537.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,116.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,713.00 Cr. (Mar 2025) to 3,116.00 Cr., marking an increase of 1,403.00 Cr..
- For CWIP, as of Sep 2025, the value is 357.00 Cr.. The value appears strong and on an upward trend. It has increased from 256.00 Cr. (Mar 2025) to 357.00 Cr., marking an increase of 101.00 Cr..
- For Investments, as of Sep 2025, the value is 454.00 Cr.. The value appears strong and on an upward trend. It has increased from 337.00 Cr. (Mar 2025) to 454.00 Cr., marking an increase of 117.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,641.00 Cr.. The value appears strong and on an upward trend. It has increased from 725.00 Cr. (Mar 2025) to 1,641.00 Cr., marking an increase of 916.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,568.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,031.00 Cr. (Mar 2025) to 5,568.00 Cr., marking an increase of 2,537.00 Cr..
Notably, the Reserves (3,749.00 Cr.) exceed the Borrowings (451.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 89.00 | 199.00 | 300.00 | 485.00 | 504.00 | 341.00 | 96.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 142 | 51 | 37 | 65 | 30 | 46 | 87 |
| Inventory Days | 556 | 278 | 243 | 259 | 279 | 268 | 199 |
| Days Payable | 190 | 113 | 100 | 97 | 63 | 49 | 96 |
| Cash Conversion Cycle | 509 | 217 | 180 | 228 | 247 | 265 | 190 |
| Working Capital Days | 205 | 64 | 56 | 108 | 99 | 108 | 74 |
| ROCE % | 50% | 40% | 41% | 32% | 19% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Flexi Cap Fund | 4,000,000 | 0.24 | 225.76 | N/A | N/A | N/A |
| Invesco India Contra Fund | 3,598,511 | 0.99 | 203.1 | 3,323,946 | 2025-12-15 01:49:31 | 8.26% |
| HDFC Balanced Advantage Fund | 3,353,052 | 0.18 | 189.25 | 2,500,285 | 2025-12-15 01:49:31 | 34.11% |
| DSP ELSS Tax Saver Fund | 3,285,254 | 1.06 | 185.42 | 1,910,066 | 2025-12-07 02:39:30 | 72% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 3,068,016 | 2.68 | 173.16 | N/A | N/A | N/A |
| DSP Healthcare Fund | 2,967,600 | 5.27 | 167.49 | 2,489,539 | 2025-12-07 02:39:30 | 19.2% |
| DSP Large & Mid Cap Fund | 2,762,648 | 0.91 | 155.92 | N/A | N/A | N/A |
| Axis Small Cap Fund | 2,540,619 | 0.54 | 143.39 | 2,026,449 | 2025-12-07 02:39:30 | 25.37% |
| DSP Flexi Cap Fund | 2,453,891 | 1.12 | 138.5 | 1,830,535 | 2025-12-07 02:39:30 | 34.05% |
| Canara Robeco Small Cap Fund | 2,261,293 | 0.98 | 127.63 | 1,574,180 | 2025-12-07 02:39:30 | 43.65% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 10.52 | 11.80 | 16.16 | 17.83 | 14.23 |
| Diluted EPS (Rs.) | 10.45 | 11.80 | 16.16 | 17.83 | 14.23 |
| Cash EPS (Rs.) | 13.44 | 13.94 | 18.03 | 17.75 | 13.37 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 66.64 | 80.56 | 68.16 | 59.99 | 46.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 66.64 | 80.56 | 68.16 | 59.99 | 46.39 |
| Revenue From Operations / Share (Rs.) | 47.04 | 41.30 | 52.65 | 51.86 | 39.66 |
| PBDIT / Share (Rs.) | 17.04 | 18.37 | 24.08 | 26.39 | 17.86 |
| PBIT / Share (Rs.) | 13.99 | 16.23 | 22.20 | 24.85 | 16.62 |
| PBT / Share (Rs.) | 13.51 | 15.94 | 21.99 | 24.61 | 16.26 |
| Net Profit / Share (Rs.) | 10.40 | 11.80 | 16.16 | 16.21 | 12.12 |
| NP After MI And SOA / Share (Rs.) | 10.52 | 11.80 | 16.16 | 17.83 | 14.23 |
| PBDIT Margin (%) | 36.21 | 44.48 | 45.72 | 50.88 | 45.03 |
| PBIT Margin (%) | 29.74 | 39.29 | 42.16 | 47.92 | 41.90 |
| PBT Margin (%) | 28.71 | 38.58 | 41.76 | 47.45 | 40.99 |
| Net Profit Margin (%) | 22.10 | 28.56 | 30.68 | 31.25 | 30.56 |
| NP After MI And SOA Margin (%) | 22.36 | 28.56 | 30.68 | 34.37 | 35.88 |
| Return on Networth / Equity (%) | 15.78 | 14.64 | 23.70 | 29.71 | 30.68 |
| Return on Capital Employeed (%) | 13.36 | 19.24 | 31.27 | 39.07 | 33.71 |
| Return On Assets (%) | 8.83 | 13.32 | 20.92 | 24.80 | 24.57 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
| Total Debt / Equity (X) | 0.04 | 0.01 | 0.04 | 0.06 | 0.11 |
| Asset Turnover Ratio (%) | 0.45 | 0.49 | 0.70 | 0.80 | 0.79 |
| Current Ratio (X) | 2.43 | 11.82 | 6.37 | 5.36 | 2.57 |
| Quick Ratio (X) | 1.98 | 9.65 | 4.40 | 4.02 | 1.66 |
| Inventory Turnover Ratio (X) | 6.02 | 3.87 | 1.44 | 1.90 | 1.65 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 49.51 | 22.43 | 7.02 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 44.36 | 20.65 | 6.46 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 50.49 | 77.57 | 92.98 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 55.64 | 79.35 | 93.54 |
| Interest Coverage Ratio (X) | 35.12 | 62.77 | 112.74 | 107.82 | 49.73 |
| Interest Coverage Ratio (Post Tax) (X) | 22.44 | 41.30 | 76.66 | 67.23 | 34.75 |
| Enterprise Value (Cr.) | 29662.03 | 17211.94 | 12039.36 | 15779.11 | 12742.73 |
| EV / Net Operating Revenue (X) | 24.77 | 16.37 | 8.98 | 11.95 | 12.62 |
| EV / EBITDA (X) | 68.38 | 36.80 | 19.64 | 23.49 | 28.02 |
| MarketCap / Net Operating Revenue (X) | 24.66 | 16.38 | 8.98 | 11.92 | 12.49 |
| Retention Ratios (%) | 0.00 | 0.00 | 50.48 | 77.56 | 92.97 |
| Price / BV (X) | 17.40 | 8.40 | 6.93 | 10.30 | 10.68 |
| Price / Net Operating Revenue (X) | 24.66 | 16.38 | 8.98 | 11.92 | 12.49 |
| EarningsYield | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 |
After reviewing the key financial ratios for Cohance Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.52. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.52, marking a decrease of 1.28.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.45. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.45, marking a decrease of 1.35.
- For Cash EPS (Rs.), as of Mar 25, the value is 13.44. This value is within the healthy range. It has decreased from 13.94 (Mar 24) to 13.44, marking a decrease of 0.50.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.64. It has decreased from 80.56 (Mar 24) to 66.64, marking a decrease of 13.92.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.64. It has decreased from 80.56 (Mar 24) to 66.64, marking a decrease of 13.92.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 47.04. It has increased from 41.30 (Mar 24) to 47.04, marking an increase of 5.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 17.04. This value is within the healthy range. It has decreased from 18.37 (Mar 24) to 17.04, marking a decrease of 1.33.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.99. This value is within the healthy range. It has decreased from 16.23 (Mar 24) to 13.99, marking a decrease of 2.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.51. This value is within the healthy range. It has decreased from 15.94 (Mar 24) to 13.51, marking a decrease of 2.43.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.40. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.40, marking a decrease of 1.40.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.52. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.52, marking a decrease of 1.28.
- For PBDIT Margin (%), as of Mar 25, the value is 36.21. This value is within the healthy range. It has decreased from 44.48 (Mar 24) to 36.21, marking a decrease of 8.27.
- For PBIT Margin (%), as of Mar 25, the value is 29.74. This value exceeds the healthy maximum of 20. It has decreased from 39.29 (Mar 24) to 29.74, marking a decrease of 9.55.
- For PBT Margin (%), as of Mar 25, the value is 28.71. This value is within the healthy range. It has decreased from 38.58 (Mar 24) to 28.71, marking a decrease of 9.87.
- For Net Profit Margin (%), as of Mar 25, the value is 22.10. This value exceeds the healthy maximum of 10. It has decreased from 28.56 (Mar 24) to 22.10, marking a decrease of 6.46.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 22.36. This value exceeds the healthy maximum of 20. It has decreased from 28.56 (Mar 24) to 22.36, marking a decrease of 6.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.78. This value is within the healthy range. It has increased from 14.64 (Mar 24) to 15.78, marking an increase of 1.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.36. This value is within the healthy range. It has decreased from 19.24 (Mar 24) to 13.36, marking a decrease of 5.88.
- For Return On Assets (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has decreased from 13.32 (Mar 24) to 8.83, marking a decrease of 4.49.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.04. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.04, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.45. It has decreased from 0.49 (Mar 24) to 0.45, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 2.43. This value is within the healthy range. It has decreased from 11.82 (Mar 24) to 2.43, marking a decrease of 9.39.
- For Quick Ratio (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 9.65 (Mar 24) to 1.98, marking a decrease of 7.67.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.02. This value is within the healthy range. It has increased from 3.87 (Mar 24) to 6.02, marking an increase of 2.15.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 35.12. This value is within the healthy range. It has decreased from 62.77 (Mar 24) to 35.12, marking a decrease of 27.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 22.44. This value is within the healthy range. It has decreased from 41.30 (Mar 24) to 22.44, marking a decrease of 18.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 29,662.03. It has increased from 17,211.94 (Mar 24) to 29,662.03, marking an increase of 12,450.09.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 24.77. This value exceeds the healthy maximum of 3. It has increased from 16.37 (Mar 24) to 24.77, marking an increase of 8.40.
- For EV / EBITDA (X), as of Mar 25, the value is 68.38. This value exceeds the healthy maximum of 15. It has increased from 36.80 (Mar 24) to 68.38, marking an increase of 31.58.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 24.66. This value exceeds the healthy maximum of 3. It has increased from 16.38 (Mar 24) to 24.66, marking an increase of 8.28.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 17.40. This value exceeds the healthy maximum of 3. It has increased from 8.40 (Mar 24) to 17.40, marking an increase of 9.00.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 24.66. This value exceeds the healthy maximum of 3. It has increased from 16.38 (Mar 24) to 24.66, marking an increase of 8.28.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cohance Lifesciences Ltd:
- Net Profit Margin: 22.1%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.36% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.78% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 22.44
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.98
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 59.7 (Industry average Stock P/E: 53.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.04
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 22.1%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 215 Atrium, C Wing, 8th Floor, Mumbai Maharashtra 400093 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vivek Sharma | Executive Chairman |
| Dr. V Prasada Raju | Managing Director |
| Mr. Pankaj Patwari | Non Executive Director |
| Ms. Shweta Jalan | Non Executive Director |
| Mr. Vinod Padikkal | Non Executive Director |
| Mr. Vinod Rao | Independent Director |
| Mr. K G Ananthakrishnan | Independent Director |
| Mr. U B Pravin Rao | Independent Director |
| Ms. Matangi Gowrishankar | Independent Director |
| Mr. Jai Shankar Krishnan | Independent Director |
FAQ
What is the intrinsic value of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd's intrinsic value (as of 25 December 2025) is 612.50 which is 14.27% higher the current market price of 536.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 20,513 Cr. market cap, FY2025-2026 high/low of 1,328/518, reserves of ₹3,749 Cr, and liabilities of 5,568 Cr.
What is the Market Cap of Cohance Lifesciences Ltd?
The Market Cap of Cohance Lifesciences Ltd is 20,513 Cr..
What is the current Stock Price of Cohance Lifesciences Ltd as on 25 December 2025?
The current stock price of Cohance Lifesciences Ltd as on 25 December 2025 is 536.
What is the High / Low of Cohance Lifesciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Cohance Lifesciences Ltd stocks is 1,328/518.
What is the Stock P/E of Cohance Lifesciences Ltd?
The Stock P/E of Cohance Lifesciences Ltd is 59.7.
What is the Book Value of Cohance Lifesciences Ltd?
The Book Value of Cohance Lifesciences Ltd is 99.0.
What is the Dividend Yield of Cohance Lifesciences Ltd?
The Dividend Yield of Cohance Lifesciences Ltd is 0.00 %.
What is the ROCE of Cohance Lifesciences Ltd?
The ROCE of Cohance Lifesciences Ltd is 14.9 %.
What is the ROE of Cohance Lifesciences Ltd?
The ROE of Cohance Lifesciences Ltd is 12.7 %.
What is the Face Value of Cohance Lifesciences Ltd?
The Face Value of Cohance Lifesciences Ltd is 1.00.